Functional Service Provider (FSP) Medical Writing

Dedicated, sponsor-aligned medical writers embedded within your organization to provide scalable expertise across the development lifecycle.  

Embedded Medical Writing

When development portfolios expand, organizational structures shift, or internal teams reach capacity; medical writing can quickly become a bottleneck to regulatory progress.

ProPharma's FSP Medical Writing model provides dedicated, sponsor-aligned writers who integrate seamlessly into your organization, delivering continuity, scalability, and deep therapeutic expertise without increasing permanent headcount.

FSP models don't just add capacity, they create meaningful "organizational leverage". By shifting the operational management to the FSP partner, organizations significantly reduce administrative burden and unlock strategic capacity. Internal teams are no longer absorbed by managing the day-to-day execution and can instead focus on high-impact priorities such as advancing scientific strategy, shaping regulatory positions, and driving portfolio-level decisions.

Rather than outsourcing individual documents, this model delivers long-term capability: a stable team that operates within your processes, systems, and governance framework.

For project‑based deliverables, explore our Global Medical Writing & Transparency services.

Why Organizations Turn to FSP Medical Writing

Many sponsors adopt an FSP model during periods of transition, growth, or sustained volume pressure. Common drivers include:

  • Acquisition or in-licensing of new compounds that strain existing resources
  • Organizational restructuring that shifts ownership of programs or therapeutic areas
  • Lack of specialized expertise required for complex or niche document types
  • Headcount or budget constraints that prevent permanent hiring
  • Sudden increases in document volume during key development phases
  • Temporary staffing gaps due to extended leave or internal redeployment
  • Learn more about our broader Functional Service Provider capabilities.

Pharma-New-Blogs-8

A Seamless Extension of Your Internal Team

Dedicated FSP writers function as an extension of your internal medical writing organization. We use your SOPs, templates, quality expectations, systems, and governance structure, participating in established communication and review processes. This embedded approach reduces onboarding time, preserves institutional knowledge, and enables consistent output across programs.

Support Across the Development Continuum

FSP Medical Writing teams can support document development across all stages of the drug development lifecycle:

computer-system-validation

Non-Clinical Development

  • Study reports and summaries
  • Investigator's Brochure (Tox, ADME, CMC, etc.)
  • Pharmacology and toxicology documentation
Submissions

Clinical & Regulatory Development

  • Protocols, protocol amendments, and Informed Consent Forms (ICFs)
  • Clinical study reports (CSRs)
  • IND/NDA/BLA submission documentation
  • Safety narratives and summaries
  • Briefing packages and health authority responses
full-service-clinical-trials

Post-Market Safety & Lifecycle Management

  • Periodic safety reports
  • Benefit-risk assessments
  • Lifecycle maintenance documentation
global-literature-review

Publications & Scientific Communication

  • Manuscripts and abstracts
  • Conference materials and presentations
  • Literature reviews and scientific summaries

Peer-Reviewed Journals & Scientific Support

Publishing in peer-reviewed journals is essential for scientific credibility, regulatory engagement, and clinical adoption. FSP teams provide dedicated support across the publication lifecycle: Manuscripts and abstracts

  • Manuscript development for peer-reviewed journals
  • Abstract preparation and conference submissions
  • Journal selection guidance
  • Literature synthesis and evidence framing
  • Author coordination and review management
  • Response-to-reviewer preparation and revisions
  • Compliance with publication guidelines (e.g., ICMJE, GPP)
  • Alignment with Medical Affairs publication strategies
Hands typing on laptop
Woman pointing her coworkers to something on a laptop

Tailored Support Across Biopharma and MedTech

ProPharma supports biotech, pharmaceutical, and medical device/diagnostics organizations navigating diverse regulatory pathways and evidence requirements. Teams are matched to program complexity, therapeutic area, and modality to ensure relevant expertise and regulatory alignment.

Flexible, Scalable Team Structures

FSP Medical Writing solutions are designed to scale with evolving program needs:
  • Single dedicated writers for focused support
  • Multi-writer teams aligned to large portfolios
  • Therapeutic-area specialists
  • Regional expertise for global development
  • Rapid scale-up or scale-down as priorities shift

When an FSP Model is the Right Choice

This model is particularly effective when organizations require ongoing support across multiple programs, predictable demand over extended timelines, integration with internal teams, or scalability without hiring delays.

Shifting operational responsibilities can help reduce administrative and operational burden, allowing internal teams to reclaim time and focus. The result is a more agile, strategically aligned writing function that supports faster, more confident organizational progress.

AdobeStock_714056211

Build the Team That Moves Your Pipeline Forward

Our FSP Medical Writing solutions provide the stability, expertise, and flexibility needed to sustain development momentum, even as priorities evolve. Contact our team to discuss how an embedded medical writing model can support your organization’s goals.

News & Insights

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and Operational Readiness

August 10, 2026

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and O...

Discover why a solid digital transformation strategy is crucial before investing in AI, ensuring successful adoption and measurable impact in life sciences.

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

News & Insights

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and Operational Readiness

August 10, 2026

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and O...

Discover why a solid digital transformation strategy is crucial before investing in AI, ensuring successful adoption and measurable impact in life sciences.

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Previous Resource Arrow Next Resource Arrow
From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Previous Webinar Arrow Next Webinar Arrow